+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area, Type of Aptamer, Target Indication, Route of Administration, Scale of Operation, Focus Area, Company Size and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • ID: 5570981
  • Report
  • April 2022
  • Region: Global
  • 350 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 2bind
  • Genomictree
  • Jena Bioscience
  • MultiplexDX
  • Otsuka Pharmaceutical
  • SBI Pharmaceuticals
Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential of aptamers as theranostic agents. In the following year, the outstanding annual sales (USD 200 million) of the aforementioned product further bolstered the confidence of industry stakeholders in this new therapeutic modality, creating lucrative opportunity for therapy developers. Further, over 100 clinical trials, along with several preclinical studies, have demonstrated the potential of aptamers as a safe and effective treatment modality, owing to their unique characteristics, such as high binding affinity and specificity. Given the various advantages, aptamer-based therapeutics in the current pipeline are targeting a range of therapeutic areas, such as oncological disorders, ophthalmological disorders and metabolomic disorders. It is worth mentioning that, in order to further enhance their performance, aptamers can be linked with various diagnostic agents, using physical or chemical conjugation. Moreover, to ensure the development of more effective therapy candidates, several players have developed novel aptamer-based technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment. In addition, post the onset of COVID-19 pandemic, there has been a significant rise in the demand for COVID-19 testing kits, which has prompted several companies to develop aptamer-based diagnostic tools for the detection of SARS-CoV-2. Consequently, to support the various initiatives undertaken by industry players, investments worth over USD 1.3 billion have been reported in the past five years. 

Presently, a significant portion of the existing manufacturing capabilities and expertise in this domain belongs to more than 50 contract service providers. Therefore, several researchers and therapy / diagnostic developers prefer to outsource their aptamer manufacturing operations. Given the rise in global disease burden over the past few years, there has been an evident increase in the demand for effective targeted therapies along with novel diagnostic approaches to reduce development timelines and investments. We believe that, with an increase in the number of aptamer-based therapies being developed and subsequent advancement of therapies across various stages of clinical trials, and their eventual commercialization, the opportunities for custom / contract service providers is likely to increase in the foreseen future. Overall, aptamer therapeutics, technologies and services market is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.


Scope of the Report


The “Aptamers: Therapeutics, Technologies and Services Market, Distribution by Application Area (Therapeutics, Research and Diagnostics), Type of Aptamer (DNA, RNA and Peptide), Target Indication (Geographic Atrophy, Macular Degeneration, Von Willebrand Diseases, Hemophilia A), Route of Administration (Intravitreal, Intravenous, Subcutaneous), Scale of Operation (Small Scale, Medium Scale and Large Scale), Focus Area (Product Development, Product Commercialization, Technology Integration, Technology Utilization and Others), Company Size (Very Small, Small, Mid-sized, Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential associated with the aptamer-based therapies, technologies and services market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.


Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in the development of aptamer-based therapeutics, along with information on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers, L-RNA aptamers and peptide aptamers), location of headquarters, phase of development (discovery, pre-clinical, clinical and approved), line of treatment (1st and 2nd line of treatment), mechanism of action, route of administration (intravenous, intravitreal and subcutaneous), type of therapy (monotherapy and combinational therapy), therapeutic area (bleeding disorders, bone disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders and ophthalmological disorders) and target indication (geographic atrophy, macular degeneration, stroke, acute stroke, ischemic stroke, multiple myeloma, chronic lymphocytic leukemia, metastatic pancreatic cancer and others).
  • A detailed overview of the current market landscape of players engaged in the development of aptamer-based technologies, based on several relevant parameters, such as year of establishment, company size, type of aptamer (DNA aptamers, RNA aptamers and peptide aptamers), location of headquarters, status of development (concept, under development and commercialized), type of technology used (SELEX, NGS, ELISA and others), application area (research, diagnostic and therapeutic purposes), purpose of technology (Characterization, drug discovery, drug development, identification, biomarker discovery, assay, validation and others), type of analyte (serum, plasma, saliva and others), therapeutic area (autoimmune disorders, infectious disorders, neurodegenerative disorders, neurological disorders, antibiotic resistance, bone disorders, CNS disorders, genetic disorders, infectious diseases, nephrological disorders, oncological disorders, ophthalmological disorders, oral diseases and psychological disorders) and target indication (amyotrophic lateral sclerosis, breast cancer , colon cancer, dengue virus, liver cancer, prostate cancer, porcine reproductive and respiratory syndrome virus (PRRSv), mycoplasma hyopneumoniae, stomach cancer and others).
  • A detailed overview of the current market landscape of aptamer-based service providers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service provider (contract research organizations, contract manufacturing organizations and third-party service providers), scale of operation (small, medium and large scale), area of application (therapeutic, diagnostic and others), type of technology used (ELISA, NGS, SELEX and others), type of technology platform (computational and others), and types of analysis offered (discovery, screening, characterization, synthesis, modification and purification).
  • A detailed competitiveness analysis of aptamer-based service providers, based on several relevant parameters, such as supplier strength (in terms of years of experience), portfolio strength (in terms of number of services offered) and portfolio diversity (based on scale of operation, area of application, technology used and types of analysis offered).
  • An insightful competitiveness analysis of aptamer-based technologies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on type of aptamer, status of development, area of application, type of technology used and purpose of technology).
  • An insightful product competitiveness analysis, benchmarking aptamer-based therapies, based on supplier strength (in terms of years of experience), and portfolio diversity (based on phase of development, line of treatment, type of therapy, route of administration and target indication).
  • An analysis on the recent developments within the aptamers industry, highlighting information on several partnerships and collaborations that have been established in this domain, during the period 2016-2021. 
  • A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters, such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2016-2021.
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects focused on aptamers, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • A detailed review of close to 390 peer-reviewed, scientific articles related to research on aptamers, based on several parameters, such as year of publication, type of publication, and popular keywords. The chapter also provides information on the top journals, top institutes and top authors (in terms of number of articles published).
  • An in-depth analysis of patents related to aptamer-based therapies and technologies, filed / granted since 2016, based on several relevant parameters, such as publication year, geographical location / patent jurisdiction, legal status, CPC symbols, emerging focus areas, type of applicant and leading players (by number of patents). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active players and regional distribution of trials.
  • An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of technologies offered, type of aptamer, status of development, area of application, type of technology used and purpose of technology.
  • Elaborate profiles of prominent players (shortlisted based our proprietary scoring criteria) engaged in this domain. Each company profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key executives. It also includes details on their respective product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent technologies (shortlisted based our proprietary scoring criteria) developed by players engaged in this domain. Each technology profile features a brief overview of the company, along with information on its year of establishment, number of employees, location of headquarters and key members of the executive team. It also includes details on their respective technology portfolio, recent developments and an informed future outlook.
  • An informed estimate of the annual clinical and commercial demand for aptamer-based therapeutics, taking into account the target patient population in ongoing and planned clinical trials focused on aptamer-based therapies, sponsored by both industry and non-industry players.


One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the aptamer-based therapies, technologies and services market. We have provided an informed estimate of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] application area (therapeutics, research and diagnostics), [B] type of aptamer (DNA, RNA and peptide), [C] target indication (geographic atrophy, macular degeneration, Von Willebrand diseases, hemophilia A), [D] route of administration (intravitreal, intravenous, subcutaneous), [E] scale of operation (clinical and commercial), [F] focus area (product development, product commercialization, technology integration, technology utilization and others), [G] company size (very small, small, mid-sized, large and very large) and [H] key geographical regions (North America, Europe, Asia-Pacific And Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.


Key Questions Answered

  • Who are the key players engaged in the development of aptamer-based therapeutics and technologies?
  • Which are the key drugs being evaluated across early and late stages of development?
  • Which companies are actively involved providing aptamer-based services? 
  • What is the evolving trend of publications focused on aptamer-based therapeutics and technologies?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in this domain? 
  • Which companies are actively filing patents to drive innovation in this niche segment?
  • What are the different initiatives undertaken by start-up players for the development of aptamer-based technologies in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 2bind
  • Genomictree
  • Jena Bioscience
  • MultiplexDX
  • Otsuka Pharmaceutical
  • SBI Pharmaceuticals

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Aptamers
3.2.1. Systematic Evolution of Ligands by Exponential Enrichment (SELEX)
3.3. Types of Aptamers
3.3.1. DNA Aptamers
3.3.2. RNA Aptamers
3.3.3. Peptide Aptamers
3.3.4. XNA Aptamers
3.4. Need for Aptamer Modifications
3.5. Advantages of Aptamers
3.6. Limitations of Aptamers
3.7. Applications of Aptamers
3.8. Future Anticipated Trends and Opportunities
4. MARKET OVERVIEW: THERAPEUTIC CANDIDATES
4.1. Chapter Overview
4.2. Aptamer-based Therapeutics: Market Landscape
4.2.1. Analysis by Type of Aptamer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Mechanism of Action
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Type of Therapy
4.3. Aptamer-based Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies
5. MARKET OVERVIEW: TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Aptamer-based Technologies: Market Landscape
5.2.1. Analysis by Type of Aptamer
5.2.2. Analysis by Status of Development
5.2.3. Analysis by Application Area
5.2.4. Analysis by Type of Technology Used
5.2.5. Analysis by Purpose of Technology
5.2.6. Analysis by Type of Analyte
5.2.7. Analysis by Therapeutic Area
5.2.8. Analysis by Target Indication
5.2.9. Analysis by Application Area, Purpose of Technology and Region
5.3. Aptamer-based Technologies: Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Company Size and Location of Headquarters
6. MARKET OVERVIEW: SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Aptamer-based Service Providers: Market Landscape
6.2.1. Analysis by Type of Service Provider
6.2.2. Analysis by Scale of Operation
6.2.3. Analysis by Application Area
6.2.4. Analysis by Type of Technology Used
6.2.5. Analysis by Type of Technology Platform
6.2.6. Analysis by Types of Analysis Offered
6.2.7. Analysis by Type of Service Provider, Type of Analysis Offered and Region
6.3. Aptamer-based Service Providers: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. Aptamer-based Service Providers: Company Competitiveness Analysis
7.3.1. Very Small Companies (Peer Group 1)
7.3.2. Small Companies (Peer Group 2)
7.3.3. Mid-sized Companies (Peer Group 3)
7.3.4. Large Companies (Peer Group 4)
7.3.5. Very Large Companies (Peer Group 5)
8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Aptamer-based Technology Providers
8.3.1. Very Small Companies (Peer Group 1)
8.3.2. Small Companies (Peer Group 2)
8.3.3. Mid-sized Companies (Peer Group 3)
8.3.4. Large Companies (Peer Group 4)
8.3.5. Very Large Companies (Peer Group 5)
9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Aptamer-based Therapeutics
9.3.1. Very Small Companies (Peer Group 1)
9.3.2. Small Companies (Peer Group 2)
9.3.3. Mid-sized Companies (Peer Group 3)
9.3.4. Large Companies (Peer Group 4)
9.3.5. Very Large Companies (Peer Group 5)
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Aptamer Therapeutics, Technologies and Service Providers: List of Partnerships and Collaborations
10.1.1 Analysis by Year, 2016-2021
10.1.2. Analysis by Type of Partnership
10.1.3. Analysis by Year and Type of Partnership
10.1.4. Analysis by Type of Partner
10.1.5. Analysis by Year and Type of Partner
10.1.6. Analysis by Type of Partnership and Type of Partner
10.1.7. Analysis by Focus Area
10.1.8. Most Active Players: Analysis by Number of Partnerships
10.1.9. Analysis by Region (Continent-wise)
10.1.9.1 Intercontinental and Intracontinental Agreements
10.1.10. Analysis by Region (Country-wise)
10.1.9.1 Local and International Agreements
11. FUNDING AND INVESTMENTS
11.1. Aptamer Therapeutics, Technologies and Service Providers: List of Funding and Investments
11.1.1. Cumulative Analysis of Instances by Year, 2016-2021
11.1.2. Analysis of Instances by Type of Funding
11.1.3. Analysis of Instances by Year and Type of Funding, 2016-2021
11.1.4. Cumulative Analysis of Amount Invested by Year, 2016-2021
11.1.5. Analysis of Amount Invested by Type of Funding
11.1.6. Analysis of Type of Funding and Amount Invested by Year, 2016-2021
11.1.7. Analysis of Instances by Region
11.1.8. Analysis of Total Amount Invested by Region
11.1.9. Most Active Players: Analysis by Number of Instances
11.1.10. Most Active Players: Analysis by Amount Raised
11.1.11. Most Active Investors: Analysis by Number of Instances
12. GRANTS ANALYSIS
12.1. Aptamer Therapeutics, Technologies and Service Providers: List of Academic Grants
12.1.1. Cumulative Year-wise Trend of Grants, 2016-2021
12.1.2. Analysis by Grant Amount
12.1.3. Analysis by Activity Codes
12.1.4. Analysis by Support Period
12.1.5. Analysis by Purpose of Grant
12.1.6. Analysis by Type of Grant
12.1.7. Analysis by Funding Institute and Support Period
12.1.8. Analysis by Type of Organization
12.1.9. Most Popular Recipient Organization: Analysis by Number of Instances
12.1.10. Most Popular Recipient Organization: Analysis by Amount Granted
12.1.11. Most Popular Recipient Organization: Distribution in US
12.1.12. Prominent Program Officers: Analysis by Number of Grants
12.1.13. Analysis by Study Section
12.1.14. Analysis by Most Popular Department
12.1.15. Word Cloud of Popular NIH Spending Categories
13. PUBLICATION ANALYSIS
13.1. Aptamer Therapeutics, Technologies and Service Providers: List of Publications
13.1.1. Analysis by Quarterly Trend of Publications (2021)
13.1.2. Analysis by Type of Publication
13.1.3. Analysis by Most Popular Journal
13.1.4. Analysis by Most Popular Author
13.1.5. Analysis by Most Popular Publisher
13.1.6. Analysis by Most Popular Copyright Holder
13.1.7. Analysis by Most Popular Keywords
13.1.8. Analysis by Affiliation
13.1.9. Analysis by Affiliation and Geography
13.1.10. Analysis by Funding Institutes
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Aptamer Therapeutics, Technologies and Service Providers: Patent Analysis
14.3.1. Analysis by Type of Patent
14.3.2. Analysis by Granted Patents
14.3.3. Analysis by Publication Year
14.3.4. Year-wise Trend of Filed Patent Applications
14.3.5. Analysis by Issuing Authority
14.3.6. Analysis by Patent Focus
14.3.7. Analysis by Patent Age
14.3.8. Analysis by CPC Symbols
14.3.9. Analysis by Type of Applicant
14.3.10. Leading Players: Analysis by Number of Patents
15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Aptamer-based Therapeutics: List of Clinical Trials
15.3.1. Analysis by Trial Status
15.3.2. Analysis by Trial Registration Year
15.3.3. Analysis by Trial Status and Trial Registration Year
15.3.4. Analysis by Number of Patients Enrolled and Phase of Development
15.3.5. Analysis by Type of Sponsor
15.3.6. Analysis by Target Patient Group
15.3.7. Analysis by Study Type
15.3.8. Analysis by Type of Masking
15.3.9. Analysis by Type of Interventional Model
15.3.10. Analysis by Primary Purpose of Trial
15.3.11. Analysis of Enrolled Patient Population by Geography
16. START-UP HEALTH INDEXING
16.1. START-UP HEALTH INDEXING
16.2. Start-ups Focused on Aptamer-based Technology Providers
16.3. Methodology and Key Parameters
16.4. Analysis by Number of Technologies
16.4.1. Analysis by Type of Aptamer
16.4.2. Analysis by Status of Development
16.4.3. Analysis by Area of Application
16.4.4. Analysis by Type of Bioanalytical Technology Used
16.4.5. Analysis by Technology Application Area
16.4.6. Analysis by Patent Count
16.4.7. Start-ups Health Indexing: Publisher Perspective
17. COMPANY PROFILES
17.1. Chapter Overview
17.2. Ajinomoto Bio-Pharma Services
17.2.1. Company Overview
17.2.2. Financial Information
17.2.3. Service Portfolio
17.2.4. Recent Developments and Future Outlook
17.3. BioSpring
17.3.1. Company Overview
17.3.2. Service Portfolio
17.3.3. Recent Developments and Future Outlook
17.4. CliniSciences
17.4.1. Company Overview
17.4.2. Service Portfolio
17.4.3. Recent Developments and Future Outlook
17.5. New England Biolabs
17.5.1. Company Overview
17.5.2. Product Portfolio
17.5.3. Recent Developments and Future Outlook
17.6. LGC Biosearch Technologies
17.6.1. Company Overview
17.6.2. Financial Information
17.6.3. Product Portfolio
17.6.4. Recent Developments and Future Outlook
17.7. Nitto Denko Avecia
17.7.1. Company Overview
17.7.2. Service Portfolio
17.7.3. Manufacturing Facilities and Capabilities
17.7.4. Recent Developments and Future Outlook
17.8. CMIC Group
17.8.1. Company Overview
17.8.2. Product Portfolio
17.8.3. Recent Developments and Future Outlook
18. TECHNOLOGY PROFILES
18.1. Chapter Overview
18.2. SomaLogic
18.2.1. Company Overview
18.2.2. Technology Overview
18.2.3. SomaScan
18.2.4. Recent Developments and Future Outlook
18.3. NOXXON Pharma
18.3.1. Company Overview
18.3.2. Technology Overview
18.3.3. Recent Developments and Future Outlook
18.4. RIBOMIC
18.4.1. Company Overview
18.4.2. Financial Information
18.4.3. Technology Overview
18.4.4. Recent Developments and Future Outlook
18.5. Halo-Bio RNAi Therapeutics
18.5.1. Company Overview
18.5.2. Technology Overview
18.5.3. Recent Developments and Future Outlook
18.6. NeuroNeuro
18.6.1. Company Overview
18.6.2. Technology Overview
18.6.3. Aptamarkers
18.6.4. Recent Developments and Future Outlook
19. DEMAND ANALYSIS
19.1. Chapter Overview
19.2. Scope and Methodology
19.3. Global Demand for Aptamers
19.4. Analysis by Scale of Operation
19.4.1. Clinical Demand for Aptamers
19.4.2. Commercial Demand for Aptamers
19.5. Analysis by Region
19.5.1. Demand for Aptamers in North America
19.5.2. Demand for Aptamers in Europe
19.5.3. Demand for Aptamers in Asia-Pacific
20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Forecast Methodology
20.3. Global Aptamer Therapeutics, Technologies and Services Market, 2022-2035
20.4. Aptamer Therapeutics Market, 2022-2035
20.4.1. Aptamer Therapeutics Market: Analysis by Type of Aptamer, 2022-2035
20.4.1.1. Aptamer Therapeutics Market for DNA Aptamers, 2022-2035
20.4.1.2. Aptamer Therapeutics Market for RNA Aptamers, 2022-2035
20.4.1.3. Aptamer Therapeutics Market for L-RNA Aptamers, 2022-2035
20.4.2. Aptamer Therapeutics Market: Analysis by Target Indication, 2022-2035
20.4.2.1. Aptamer Therapeutics Market for Brain Cancer, 2022-2035
20.4.2.2. Aptamer Therapeutics Market for Geographic Atrophy, 2022-2035
20.4.2.3. Aptamer Therapeutics Market for Hemophilia A, 2022-2035
20.4.2.4. Aptamer Therapeutics Market for Macular Degeneration, 2022-2035
20.4.2.5. Aptamer Therapeutics Market for Pancreatic Cancer, 2022-2035
20.4.2.6. Aptamer Therapeutics Market for Von Willebrand Diseases, 2022-2035
20.4.3. Aptamer Therapeutics Market: Analysis by Route of Administration, 2022-2035
20.4.3.1. Aptamer Therapeutics Market for Intravenous Route, 2022-2035
20.4.3.2. Aptamer Therapeutics Market for Intravitreal Route, 2022-2035
20.4.3.3. Aptamer Therapeutics Market for Subcutaneous Route, 2022-2035
20.4.4. Aptamer Therapeutics Market: Analysis by Geography, 2022-2035
20.4.4.1. Aptamer Therapeutics Market in North America, 2022-2035
20.4.4.2. Aptamer Therapeutics Market in Europe, 2022-2035
20.4.4.3. Aptamer Therapeutics Market in Asia-Pacific, 2022-2035
20.4.4.4. Aptamer Therapeutics Market in Rest of the World, 2022-2035
20.4.5. Drug-wise Sales Forecast
20.4.5.1. Zimura (Iveric Bio)
20.4.5.1.1. Target Patient Population
20.4.5.1.2. Value Creation Analysis
20.4.5.2. NOX-A12 (NOXXON Pharma)
20.4.5.2.1. Target Patient Population
20.4.5.2.2. Value Creation Analysis
20.4.5.3. BT 200 (Guardian therapeutics)
20.4.5.3.1. Target Patient Population
20.4.5.3.2. Value Creation Analysis
20.4.5.4. BC007 (Berlin Cures)
20.4.5.4.1. Target Patient Population
20.4.5.4.2. Value Creation Analysis
20.5. Aptamer Technologies Market, 2022-2035
20.5.1. Aptamer Technologies Market: Analysis by Focus Area, 2022-2035
20.5.1.1. Aptamer Therapeutics Market for Product Development Initiatives, 2022-2035
20.5.1.2. Aptamer Therapeutics Market for Product Commercialization Initiatives, 2022-2035
20.5.1.3. Aptamer Therapeutics Market for Technology Integration Initiatives, 2022-2035
20.5.1.4. Aptamer Therapeutics Market for Technology Utilization Initiatives, 2022-2035
20.5.1.5. Aptamer Therapeutics Market for Other Initiatives, 2022-2035
20.5.2. Aptamer Technologies Market: Analysis by Company Size, 2022-2035
20.5.1.1. Aptamer Therapeutics Market for Very Small Companies, 2022-2035
20.5.1.2. Aptamer Therapeutics Market for Small Companies, 2022-2035
20.5.1.3. Aptamer Therapeutics Market for Mid-sized Companies, 2022-2035
20.5.1.4. Aptamer Therapeutics Market for Large Companies, 2022-2035
20.5.1.5. Aptamer Therapeutics Market for Very Large Companies, 2022-2035
20.5.3. Aptamer Technologies Market: Analysis by Geography, 2022-2035
20.5.3.1. Aptamer Technologies Market in North America, 2022-2035
20.5.3.2. Aptamer Technologies Market in Europe, 2022-2035
20.5.3.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035
20.6. Aptamer Services Market, 2022-2035
20.6.1. Aptamer Services Market: Analysis by Scale of Operation, 2022-2035
20.6.1.1. Aptamer Services Market for Small Scale Operations, 2022-2035
20.6.1.2. Aptamer Services Market for Medium-Scale Operations, 2022-2035
20.6.1.3. Aptamer Services Market for Large Scale Operations, 2022-2035
20.6.2. Aptamer Technologies Market: Analysis by Geography, 2022-2035
20.6.2.1. Aptamer Technologies Market in North America, 2022-2035
20.6.2.2. Aptamer Technologies Market in Europe, 2022-2035
20.6.2.3. Aptamer Technologies Market in Asia-Pacific, 2022-2035
21. CONCLUSION22. APPENDIX I: TABULATED DATA23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Note: Product cover images may vary from those shown
  • 2bind
  • Accelero ® Bioanalytics  
  • Achiko
  • Acuitas Capital
  • Admera Health
  • Aju IB
  • Allergan
  • Amgen
  • ASKA Pharmaceutical
  • AstraZeneca
  • blueconic
  • Casdin Capital
  • deCODE genetics (A Subsidiary of Amgen)
  • DeepVerge
  • Drive Therapeutics
  • EIT Health
  • Engineering and Physical Sciences Research Council (EPSRC)
  • Epsilon Molecular Engineering
  • Eurofins Genomics
  • Eurogentec
  • EVEC
  • Eyetech Pharmaceuticals    (Acquired by Valeant Pharmaceuticals)
  • Facible Biodiagnostics
  • Farallon Capital Management
  • Foresite Capital
  • G. N. Tech Venture Investment
  • GC Pharma
  • Gene Link
  • Genomictree
  • Giner
  • GlyTech
  • GNS Healthcare
  • Granzer Regulatory Consulting and Services
  • Guardian Therapeutics
  • Halo-Bio RNAi Therapeutics
  • Hanlim Pharmaceutical
  • Harvard University
  • HB Investment
  • Healios
  • Horizon Discovery
  • IBA Lifesciences
  • iCarbonX
  • ID Ventures
  • Imperial College London
  • Inception 4    (Acquired by IVERIC bio)
  • Insight Partners
  • Institute of Hematology and Transfusion Medicine
  • Integrated DNA Technologies
  • Intermountain Ventures
  • Interoligo
  • IVERIC bio
  • Iwon Medical Foundation
  • Ixaka
  • Janssen
  • Janus Henderson Investors
  • Japan Agency for Medical Research and Development (AMED)
  • Jena Bioscience
  • Juntendo University School of Medicine
  • Keio University School of Medicine
  • King’s College London
  • Kiwoom Investment
  • Korea Investment Partners
  • Kreos Capital
  • LC Sciences
  • Leeds Centre for Personalised Medicine and Health
  • LGC
  • LinkBio
  • Logos Capital
  • Lucerna
  • Madryn Asset Management
  • Maravai LifeSciences
  • Maruho
  • Masaryk University
  • Massachusetts General Hospital
  • Medical Innovation Ventures (Mediven®)
  • Medical University of Vienna
  • MeiraGTx
  • Meneldor
  • Merck
  • Metabion
  • Millennium Management
  • Ministry of Science and Innovation (Spain)
  • Mint Diagnostics
  • Mizuho Capital
  • Mologic
  • MultiplexDX
  • nal von minden
  • Nan Fung Life Sciences
  • NanoMosaic
  • National Cancer Center
  • National Center for Tumor Diseases (NCT)
  • National Institutes of General Medical Sciences (NIGMS)
  • National Institutes of Health
  • NEC
  • NEC Solution Innovators
  • Nencki Institute of Experimental Biology
  • NeoNeuro
  • NeoVentures
  • NES Biotechnology
  • NeuraMedy
  • New England Biolabs
  • New York Stem Cell Foundation Research Institute (NYSCF)
  • Nexmos
  • Nitto Avecia
  • NOVAPTECH
  • Novartis
  • Novo Nordisk
  • NOXXON Pharma
  • NVIGEN
  • Nyenburgh Investment Partners (NYIP)
  • Oak BioSciences
  • Osaka University
  • Otsuka Chemical
  • Otsuka Pharmaceutical
  • Oxford University
  • PCL    Health
  • Pecic Lab
  • Peking Union Medical College
  • PerkinElmer
  • Pfizer
  • PINOTBIO
  • ProAxsis
  • Profacgen
  • Proteovista
  • Pura Vida Investments
  • Pure Biologics
  • Qualigen Therapeutics
  • Quimigen
  • RayBiotech
  • Redmile Group
  • Regado Biosciences (A Subsidiary of Allergan)
  • Rev1 Ventures
  • Revelation Partners
  • RIBOMIC
  • Ritter Pharmaceuticals
  • Samurai Incubate
  • SB Management (A Subsidiary of SoftBank)
  • SBI Group
  • SBI Pharmaceuticals
  • Seattle Children’s Research Institute
  • Seikagaku
  • Sekisui Diagnostics
  • Showa Denko Materials
  • SMBC Venture Capital
  • SM-Sino Technology Investment
  • SomaLogic
  • Suzhou Ribo Life Science
  • Synbio Technologies
  • TAGCyx Biotechnologies
  • Taisho Pharmaceutical
  • Takeda
  • The Ohio State University
  • Tiger Gene
  • Time BioVentures
  • Tobira Therapeutics (Acquired by Allergan)
  • Torres Quevedo Grant
  • TriBiotica
  • TriLink BioTechnologies (acquired by Maravai LifeSciences)
  • Twist Bioscience
  • Ulisse BioMed
  • Univeristy College London
  • University Health Network
  • University of Hong Kong
  • University of Louisville
  • University of Manchester
  • University of Tokyo
  • Uppsala University Hospital
  • UTokyo Innovation Platform
  • ValitaCell
  • Visium Healthcare Partners
  • Vivonics
  • WuXi STA (A Subsidiary of WuXi AppTec)
  • Ziff Capital Healthcare Ventures
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...